Roles of Eph/ephrin bidirectional signaling during injury and recovery of the central nervous system

Yue Wan1*, Jin-Shan Yang2,3, Li-Cai Xu1, Xiao-Jiang Huang3, Wei Wang2, Min-Jie Xie1,*
1 Department of Neurology, The Third People’s Hospital of Hubei Province, Wuhan, Hubei Province, China
2 Department of Neurology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei Province, China
3 Department of Neurology, First Affiliated Hospital, Fujian Medical University, Fuzhou, Fujian Province, China
4 Department of Neurological Rehabilitation Center, The Third People’s Hospital of Hubei Province, Wuhan, Hubei Province, China

Funding: This study was supported by the National Natural Science Foundation of China, No. 81371312, 81030021; the National Basic Research Development Program of China (973 Program), No. 2011CB504403.

Abstract

Multiple cellular components, including neuronal, glial and endothelial cells, are involved in the sophisticated pathological processes following central nervous system injury. The pathological process cannot reduce damage or improve functional recovery by merely targeting the molecular mechanisms of neuronal cell death after central nerve system injuries. Eph receptors and ephrin ligands have drawn wide attention since the discovery of their extensive distribution and unique bidirectional signaling between astrocytes and neurons. The roles of Eph/ephrin bidirectional signaling in the developmental processes have been reported in previous research. Recent observations suggest that Eph/ephrin bidirectional signaling continues to be expressed in most regions and cell types in the adult central nervous system, playing diverse roles. The Eph/ephrin complex mediates neurogenesis and angiogenesis, promotes glial scar formation, regulates endocrine levels, inhibits myelin formation and aggravates inflammation and nerve pain caused by injury. The interaction between Eph and ephrin is also considered to be the key to angiogenesis. This review focuses on the roles of Eph/ephrin bidirectional signaling in the repair of central nervous system injuries.

Key Words: nerve regeneration; Eph/ephrin; bidirectional signaling; central nervous system; injury; recovery; neurons; glial cells

Introduction

Functional recovery after injury to the central nervous system (CNS) has been limited by failure of neurons to regenerate and restore. The molecular mechanisms underlying the processes are not fully understood. Over the past few decades, intensive studies have indicated that the extracellular environment of the CNS plays a pivotal role. The lack of neuronal regeneration may be explained partly by the lack of growth promoting molecules, together with inhibitors to axonal regeneration in the extracellular environment. The Eph receptors and their ligands, ephrins, are members of the receptor tyrosine kinase family. Since Hirai et al. (1987) first identified the EphA1 receptor, the Eph proteins have become the largest known receptor tyrosine kinase family. Fourteen members of the Eph receptor family have been found in humans and other mammals, including the EphA subfamily (EphA1–EphA8, EphA10) and the EphB subfamily (EphB1–EphB4, EphB6). The former preferentially binds to five glycosylphosphatidylinositol-anchored ephrin-A ligands (ephrinA1–A5) and the latter possesses high affinity binding domain to three transmembrane ephrin-B (ephrinB1–B3) ligands, with some promiscuity of the binding (Wilkinson, 2001; Goldshmit et al., 2006; Pasquale, 2008; Lisabeth et al., 2013; Cramer and Miko, 2016). Imbalance of Eph/ephrin function has been implicated in a wide variety of CNS injuries and diseases, summarized in Table 1. Therefore, an in-depth study of Eph/ephrin would be of great importance for the understanding of the pathophysiological mechanisms and in developing treatments of these diseases. This review discusses the effects of Eph/ephrin in the CNS, and provides an insight into developing possible routes to achieve neural repair.

Eph and Ephrins

Eph receptor family members

Since Hirai et al. (1987) first identified the EphA1 receptor, the Eph proteins have become the largest known receptor tyrosine kinase family. Fourteen members of the Eph receptor family have been found in humans and other mammals, including the EphA subfamily (EphA1–EphA8, EphA10) and the EphB subfamily (EphB1–EphB4, EphB6). The former preferentially binds to five glycosylphosphatidylinositol-anchored ephrin-A ligands (ephrinA1–A5) and the latter possesses high affinity binding domain to three transmembrane ephrin-B (ephrinB1–B3) ligands, with some promiscuity of the binding (Wilkinson, 2001; Goldshmit et al., 2006; Pasquale, 2008; Lisabeth et al., 2013; Cramer and Miko, 2016; Pasquale, 2016; Taylor et al., 2017). The signaling pathways are directly initiated by either Eph receptor or ephrin ligand activation are termed “forward signaling” and “reverse signaling” respectively (Aoto and Chen, 2007). The diverse roles of Eph/ephrin bidirectional signaling in various pathological and physiological processes have been elucidated extensively (O’Leary and Wilkinson, 1999; Wilkinson, 2001; Goldshmit et al., 2006; Chumley et al., 2007; Pasquale, 2008; Lisabeth et al., 2013; Day et al., 2014; Choi et al., 2016; Cramer and Miko, 2016; Pasquale, 2016; Taylor et al., 2017; Wei et al., 2017).
Eph structure

Although there are a large number of subtypes, Eph receptors share similar structures (summarized in Figure 1). The extracellular region of Eph receptors includes a ligand-binding site and a cysteine-rich region followed by two fibronectin type III motifs (Lackmann et al., 1998; Pasquale, 2008; Lisabeth et al., 2013; Taylor et al., 2017). The intracellular part is composed of four domains: a juxtamembrane region, a kinase domain, a sterile-alpha-motif (SAM) domain and a PSD95/Dlg/ZO1 (PDZ)-binding domain. The juxtamembrane region is critical for receptor activation (Brückner and Klein, 1998; Lisabeth et al., 2013; Taylor et al., 2017). The kinase domain is widely considered to implicate the cytoskeleton through the small GTPases (Nimnual et al., 1998). The SAM domain is involved in regulating receptor dimerization and initiating downstream signal transduction (Goldshmit et al., 2006). The fourth, PDZ domain, is critical for Eph/ephrin complexes assembly and location (Kullander and Klein, 2002; Goldshmit et al., 2006).

Ephrin structure

The ephrin ligands are also divided into two subclasses: an ephrinA subfamily and an ephrinB subfamily based on sequence conservation and affinities for Eph receptors. Both of them have a receptor-binding domain (Figure 1). The ephrinA ligands (ephrinA1–A5) are attached to the membrane at their carboxyl terminal via a glycosylphosphatidylinositol anchor, whereas the ephrinB ligands (ephrinB1-B3) have a short transmembrane domain, a PDZ-domain binding site, a short cytoplasmic tail and have five conserved tyrosine residues (Flanagan and Vanderhaeghen, 1998; Goldshmit et al., 2006; Wu et al., 2012; Lisabeth et al., 2013; Taylor et al., 2017).

Eph/ephrin complex formation and bidirectional signaling

The unique feature of Eph/ephrin signaling complexes is their ability to generate bidirectional signaling. An Eph receptor can also act as a ligand and an ephrin ligand can act as a receptor. The former signaling is termed as forward signaling, while the latter signaling is termed as reverse signaling. Both forward and reverse signaling have a role in a series of physiological process such as cell migration and adhesion, neurite outgrowth, synaptic plasticity, topographical mapping, neuronal connectivity and regeneration. It also has a role in the vascular formation in the nervous system (Mellitzer et al., 1999; Huot, 2004; Klein, 2004; Eichmann et al., 2005; Pasquale, 2008; Taylor et al., 2017). The formation of highly clustered Eph/ephrin complexes is necessary for the initiation of Eph/ephrin bidirectional signaling. Previous studies demonstrated that recombinant, soluble ephrin must be pretreated to form clustered ephrin to trigger efficient activation (Pasquale, 2008; Taylor et al., 2017), since any soluble monomeric ephrins act as Eph receptor antagonists (Carter et al., 2002; Lawrenson et al., 2002; Dobrzanski et al., 2004). The same principle also applies to reverse signaling. The degree of clustering is related to signal strength and downstream pathways (Pasquale, 2005, 2008).

Eph forward signaling induced by ephrin binding initiates downstream signal transduction after autophosphorylation and phosphorylation in the tyrosine kinase domain. Signaling pathways downstream of Eph forward signaling have been extensively studied (Henkemeyer et al., 1994; Holland et al., 1997; Becker et al., 2000; Shamah et al., 2001; Kullander and Klein, 2002; Takasu et al., 2002; Tong et al., 2003; Goldsmith et al., 2004; Pasquale, 2005, 2008; Lisabeth et al., 2013; Taylor et al., 2017). Forward signaling mediated by Eph receptors has been shown to involve regenerative processes such as neurite outgrowth and cell migration by regulating the organization of dynamic cytoskeletal and rearrangement of actin (Figure 1). The Eph receptors are highly important to the Rho GTPases, including Rac, Cdc42 and Rho that are critical in regulating the actin cytoskeleton (Giniger, 2002; Pasquale, 2008; Lisabeth et al., 2013). Forward signaling through Eph receptors inhibits axonal regeneration in neuronal cells by stimulating the collapse of the growth cone, probably acting on Rac and Cdc42 (Lehmann et al., 1999; Dickson, 2001; Dergham et al., 2002; Fournier et al., 2003). On the contrary, blocking Eph receptors leads to downstream Rac and Cdc42 activation that promotes axonal outgrowth. Therefore, EphA receptors can lead to repulsive guidance for growing axons by Rho GTPases activation. Rac and Cdc42 activation promotes axonal outgrowth through blocking Eph forward signaling (Shamah et al., 2001; Sahin et al., 2005; Lisabeth et al., 2013). Ephexin, which links EphA4 receptors to the Rho GTPases, is known to play pivotal roles in axon guidance (Shamah et al., 2001; Sahin et al., 2005). It has been demonstrated that ephrinA3 can suppress Wnt/β-catenin signaling and inhibit the neurogenic potential of retinal stem cell through EphA4 (Fang et al., 2013).

Eph forward signaling may also be involved in the Janus kinase/signal transducer and activator of the transcription (JAK/TAT) pathway, the phosphoinositide 3-kinase (PI3K) pathway and the mitogen-activated protein (MAP)-kinase pathway (Steinle et al., 2002; Lai et al., 2004; Macrae et al., 2005).

A signal through the ephrin ligand is defined as reverse signaling. Although many previous studies have shown the predominant roles played by ephrin reverse signaling, e.g. in neural progenitor proliferation, axon guidance, neuronal migration and synaptic plasticity, the intracellular signaling cascades following ephrin activation have not been investigated thoroughly. With the help of the co-receptors, ephrinAs ligands are able to trigger downstream activation of the PI3K and Src family kinases despite the lack of a cytoplasmic tail (Davy et al., 1999; Davy and Robbins, 2000) (Figure 1). It was recently demonstrated that associated transmembrane signaling partners, e.g., TrkB and p75 neurotrophin receptor (p75NTR), represent good candidates as co-receptors for ephrinAs (Sutterlin et al., 2012).

In contrast to ephrinA ligands, transmembrane ephrinB ligands have a single transmembrane domain and a short conserved cytoplasmic domain with a PDZ domain-binding motif, which constitutes the structural foundation of reverse
Figure 1 Bidirectional signaling of Eph/ephrin.

Forward signaling through Eph receptors inhibits axonal regeneration in neuronal cells by stimulating the collapse of their growth cones, probably through Rac and Cdc42. On the contrary, blocking Eph receptors, downstream Rac and Cdc42 activation will promote axonal outgrowth. Therefore, EphA receptors can lead to repulsive guidance for growing axons by Rho GTPases activation. Rac and Cdc42 activation promotes axonal outgrowth through blocking Eph forward signaling. Ephexin, which links EphA4 receptors to the Rho GTPases, is known to play pivotal roles in axon guidance. It has been demonstrated that ephrinA3 can suppress Wnt/β-catenin signaling and inhibit the neurogenic potential of retinal stem cell through EphA4. Eph forward signaling may also be involved in the Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway, phosphoinositide 3-kinase (PI3K) pathway and Mitogen-activated protein (MAP)-kinase pathway. Ephrin reverse signaling in neural progenitor proliferation, axon guidance, neuronal migration and synaptic plasticity. The intracellular signaling cascades following ephrin activation have not been investigated thoroughly. With the help of the co-receptors, ephrinA ligands are able to trigger downstream activation of PI3K and Src family kinases despite lack of a cytoplasmic tail. It was recently demonstrated that associated transmembrane signaling partners, such as TrkB and p75 neurotrophin receptor (p75NTR), represent good candidates as co-receptors for ephrinA. In contrast to ephrinA ligands, transmembrane ephrinB ligands have a single transmembrane domain and a short conserved cytoplasmic domain with a PSD95/Dlg/ZO1 (PDZ) domain-binding motif, which constitute the structural foundation of reverse signaling. Through the activation of Src-family kinases, ephrinB ligands are phosphorylated. Recent advances have discovered that Src-homology-2 (SH2)-domain-containing adaptor molecules, such as Grb4 are recruited and then phosphorylate ephrin-B ligands which further initiates downstream signaling regulating cytoskeleton dynamics. Soon afterwards, the protein tyrosine phosphatase (PTP-BL) is recruited through its PDZ domain to the ephrinB carboxy-terminal tail which dephosphorylates ephrinB and inactivates Src-family kinases. PDZ-binding proteins, as regulators of G-protein signaling 3 (PDZ-RGS3), might inhibit C-X-C chemokine receptor type 4-mediated chemotaxis by inactivating the Gαβγ-protein complex, which further regulates the migration of endothelial cells and angiogenesis.

signaling. Through the activation of the Src-family kinases, ephrinB ligands are phosphorylated. Recent advances have discovered that Src-homology-2-domain-containing adapter molecules, e.g., Grb4, are recruited and then phosphorylate ephrin-B ligands, further initiating the regulation of cytoskeleton dynamics by downstream signaling (Holland et al., 1996; Bruckner et al., 1997; Cowan and Henkemeyer, 2001; Kalo et al., 2001; Palmer et al., 2002). Then the protein tyrosine phosphatase is recruited through its PDZ domain to the ephrinB carboxy-terminal tail, which dephosphorylates ephrinB and inactivates Src-family kinases. PDZ-binding protein, as a regulator of G-protein signaling 3 (PDZ-RGS3), might inhibit C-X-C chemokine receptor type 4 (CXCR4-receptor)-mediated chemotaxis by inactivating the Gαβγ-protein complex. This regulates the endothelial migration and angiogenesis (Salcedo et al., 1999; Lu et al., 2001).
Table 1 Summary of Eph/ephrin and their associated central nervous system injuries or diseases

| No. of family member | Eph/ephrin signaling | Central nervous system injury or disease |
|----------------------|----------------------|-----------------------------------------|
| EphA1                | EphrinA1             | Glioblastoma (Day et al., 2014)         |
| EphA2                | EphrinA1; EphrinA3;  | Multiple sclerosis (MS) (Sobel, 2005);  |
|                      | EphrinA4; EphrinA5   | glioblastoma (Hafner et al., 2004)      |
| EphA3                | EphrinA1; EphrinA2;  | Subdural hematoma (Biervert et al., 2001)|
|                      | EphrinA3; EphrinA5   | ischemia stroke (Choi et al., 2016);    |
| EphA4                | EphrinA1; EphrinA2;  | Glioblastoma (Day et al., 2014);        |
|                      | EphrinA3; EphrinA4;  | MS (Sobel, 2005); optic nerve injury     |
|                      | EphrinA5; EphrinB3   | (Goldshmit et al., 2006); spinal cord    |
|                      |                      | injury (SCI) (Goldshmit et al., 2006)   |
| EphA5                | EphrinA1; EphrinA2;  | Glioblastoma (Day et al., 2014);        |
|                      | EphrinA3; EphrinA4;  | SCI (Goldshmit et al., 2006)            |
|                      | EphrinA5; EphrinB3   |                                           |
| EphA6                | EphrinA1; EphrinA2;  | Glioblastoma (Day et al., 2014);        |
|                      | EphrinA3; EphrinA4;  | SCI (Goldshmit et al., 2006)            |
|                      | EphrinA5             |                                           |
| EphA7                | EphrinA1; EphrinA2;  | Glioblastoma (Day et al., 2014);        |
|                      | EphrinA3             | MS (Sobel, 2005); SCI (Goldshmit et al.,|
|                      |                      | 2006)                                   |
| EphA8                | EphrinA2; EphrinA3;  | Glioblastoma (Day et al., 2014);        |
|                      | EphrinA4; EphrinA5   | SCI (Goldshmit et al., 2006)            |
| EphA10               | EphrinA3; EphrinA4;  | Unknown                                 |
|                      | EphrinA5             |                                           |
| EphB1                | EphrinB1; EphrinB2;  | Glioblastoma (Wei et al., 2017);        |
|                      | EphrinB3             | medulloblastoma (Wei et al., 2017);     |
|                      |                      | subdural hematoma (Biervert et al., 2001);|
|                      |                      | neuropathic pain (Yu et al., 2012)      |
| EphB2                | EphrinB1; EphrinB2;  | Glioblastoma (Day et al., 2014); SCI     |
|                      | EphrinB3; EphrinA5   | (Pasquale, 2008); medulloblastoma (Bhatia,|
|                      |                      | (Wei et al., 2017); ischemia stroke      |
|                      |                      | (Xing et al., 2008); Alzheimer’s disease (|
|                      |                      | Taylor et al., 2017)                    |
| EphB3                | EphrinB1; EphrinB2;  | Optic nerve injury (Pasquale, 2008)     |
|                      | EphrinB3             |                                           |
| EphB4                | EphrinB1; EphrinB2;  | Glioblastoma (Wei et al., 2017)         |
|                      | EphrinB3             |                                           |
| EphB6                | EphrinB1; EphrinB2;  | Glioblastoma (Day et al., 2014)         |
|                      | EphrinB3             |                                           |
| EphrinA1             | EphA1; EphA2; EphA3;| Glioblastoma (Binda et al., 2012);      |
|                      | EphA4; EphA5; EphA6;| ischemia stroke (Choi et al., 2016);    |
|                      | EphA7                | MS (Sobel, 2005); optic nerve injury     |
| EphrinA2             | EphA3; EphA4; EphA5;| Ischemia stroke (Choi et al., 2016);     |
|                      | EphA6; EphA7; EphA8  | SCI (Goldshmit et al., 2006)            |
| EphrinA3             | EphA2; EphA3; EphA4;| Ischemia stroke (Choi et al., 2016);     |
|                      | EphA5; EphA6; EphA7;| SCI (Goldshmit et al., 2006)            |
|                      | EphA8                |                                           |
| EphrinA4             | EphA2; EphA4; EphA5;| Optic nerve injury (Goldshmit et al., 2006)|
|                      | EphA6                |                                           |
| EphrinA5             | EphA2; EphA3; EphA4;| Ischemia stroke (Choi et al., 2016);     |
|                      | EphA5; EphA6; EphA8;| SCI (Goldshmit et al., 2006); optic nerve|
|                      | EphB2                | injury (Goldshmit et al., 2006);         |
| EphrinB1             | EphB1; EphB2; EphB3;| Optic nerve injury (Goldshmit et al., 2006)|
| EphrinB2             | EphA4; EphB1; EphB2;| Glioblastoma (Krusche et al., 2016); SCI |
|                      | EphB3; EphB4; EphB6;| (Pasquale, 2008); neuropathic pain        |
|                      |                      | (Zhao et al., 2010)                      |
| EphrinB3             | EphA4; EphA5; EphB1;| Glioblastoma (Day et al., 2014)         |
|                      | EphB2; EphB3; EphB4;|                                           |
|                      | EphB6                |                                           |

Eph/Ephrin Expression in Adult CNS

For many years, researchers have focused on the roles of Eph family in the developing CNS. During development, expressions of Eph receptor and ephrin ligand change significantly. In most regions and cell types of normal CNS, Ephs and ephrins continue to be expressed in adults, but at a lower level than during development (Goldshmit et al., 2006). In brain regions that show highly changeable morphological and physiological plasticity into adulthood, e.g., the amygdala and hippocampus, many Eph/ephrins continue to be expressed (Liebl et al., 2003; Pasquale, 2008). Several diverse roles of Eph/ephrins in adult CNS have been elucidated (Goldshmit et al., 2006; Pasquale, 2008; Day et al., 2014; Kania and Klein, 2016; Taylor et al., 2017; Wei et al., 2017).

Eph/ephrins are widely regarded to have an important role in regulating synapse formation as well as synaptic plasticity and function (Olivieri and Miescher, 1999; Murai and Pasquale, 2002; Takasu et al., 2002). This is especially so in processing spinal cord pain (Zhao et al., 2010) and maintaining hippocampal plasticity (Taylor et al., 2017). Several studies have shown that EphA4 forward signaling activation mediates dendritic spine retraction together with a reduction in their number and size by remodeling the actin cytoskeleton and modifying the properties of adhesion receptors (Fu et al., 2007; Klein, 2009). EphA4 knockout mice show significantly longer and overlapping spines comparing to wild-type mice (Murai et al., 2003). However, triple EphB (EphB1/EphB2/EphB3) knockout mice show a distinct decrease in spine density and formation of abnormal spines; the contrasting effects suggest that EphB forward signaling is associated with synaptic maturation and dendritic spine formation (Henkemeyer et al., 2003). Extensive studies by comparing wild-type mice and Eph/ephrin knockout show that Eph/ephrins affect memory and learning by controlling syn-
aptic formation (Martone et al., 1997; Murai and Pasquale, 2002; Murai et al., 2003; Grunwald et al., 2004; Rodenas-Ruano et al., 2006). Eph/ephrins may recruit cell-surface molecules such as the N-methyl-D-aspartic acid (NMDA) receptor through their PDZ domain (Hsueh and Sheng, 1998; Torres et al., 1998; Buchert et al., 1999; Kalo and Pasquale, 1999). EphB2/ephrinB3 bidirectional signaling can induce long-term potentiation generation by the NMDA receptor (Grunwald et al., 2001; Henderson et al., 2001; Takasu et al., 2002; Lim et al., 2008; Taylor et al., 2017).

In the hippocampus, EphA4/ephrinA3 mediated bidirectional signaling has not only been implicated in changing spine morphology and α-amino-3-hydroxy-5-methyl-4-isoxazole propionate receptor (Murai et al., 2003), but also in the regulation of hippocampal synaptic plasticity and the astrocytic glutamate transporter (Carmona et al., 2009). Others have shown that ephrinBs/EphB take part in processing spinal cord pain through NMDA receptors, P3K and its downstream signaling (Battaglia et al., 2003; Slack et al., 2008; Song et al., 2008; Ruan et al., 2010; Yu et al., 2012).

In the subventricular zone of the lateral ventricle and subgranular zone of the dentate gyrus, where there is continuous neurogenesis of stem cells, Eph/ephrins are present throughout adulthood (Goldshmit et al., 2006). Both the differentiation and proliferation of neural precursor cells can be influenced by Eph/ephrin bidirectional signaling. EphB3/ephrinB3 regulates the differentiation and proliferation of cells in the rostral migratory stream and subventricular zone by controlling the expression level of p53 (Ricard et al., 2006; del Valle et al., 2011; Baumann et al., 2013). EphA4 knockout mice exhibit decreased cell proliferation and differentiation disorder in the rostral migratory stream and subventricular zone, resulting in a reduced number of neuronal and glial progenitors (Khodosevich et al., 2011). EphB1/ephrinB3 signaling is found to affect the differentiation and proliferation of neural precursor cells in the subgranular zone of the dentate gyrus. This highlights a potential therapeutic target for neurodegenerative diseases and brain damage (Chumley et al., 2007).

The signals transduced by Eph/ephrin also impact on angiogenesis in the CNS (Pasquale, 2008). EphA2 receptor blockade is proven to improve tight junction formation between endothelial cells and to promote angiogenesis (Zhou et al., 2011). There is evidence that intracerebroventricular injection of ephrinA1 promotes angiogenesis through EphA forward signaling (Jing et al., 2012).

Expression and Regulation of Eph/Ephrin in the CNS following Injury or Diseases

Apart from their critical roles in the developing CNS, Eph/ephrin signaling is involved in the sophisticated pathophysiological processes following CNS injury or diseases (Table 1). Various studies have shown that Eph receptors and ephrin ligands upregulate after CNS injuries and exhibit diverse and changing patterns depending on when or where injuries happen (Miranda et al., 1999; Willson et al., 2002; Bundesen et al., 2003). After CNS damage, different cell types behave differently. Neurons attempt to regenerate the damaged connections. To maintain the homeostasis, astrocytes and microglial cells are activated and proliferate, while oligodendrocytes try to initiate remyelination. The changes in expression of Ephs and ephrins under these situations may reveal how the Eph/ephrin signaling functions in response to damage. Given their effect on axon guidance in developing CNS, it is commonly believed that Ephs and ephrins may play a role in regulating axonal guidance during axonal regeneration. Eph receptors and their ephrin ligands are also expressed on mature cell types, e.g. neurons and astrocytes, to mediate astrocytic gliosis, neural regeneration, vascular remodeling and neuroinflammation.

Eph/ephrin signaling affects glial scar formation and glutamate homeostasis

Eph/ephrins also act in various ways to influence the structural and functional reorganization of damaged CNS. A primary response of the Ephs and ephrins is their contribution to CNS injury by promoting the formation of a glial scar, thereby inhibiting axonal regeneration. Previous studies have revealed that sophisticated processes involved in gliosis consist of glial reactivation, extracellular matrix alteration and even collagen deposition. Multi-cellular components, including astrocytes, microglia, oligodendrocyte progenitors and fibroblasts, participate in glial scar formation (Bunge et al., 1997; Dawson et al., 2000). Ephs and ephrins are expressed on many kinds of cells related to gliosis and glial scarring and affect their cellular response to damage. Glial cells are highly sensitive to damage. During CNS injury, astrocytes and microglia are activated and start to proliferate, characterized by morphological and functional changes, then form the glia scar. Astrocytic activation presents as cellular hypertrophy, proliferation and gliosis (Schnell et al., 1999), which can even be observed in areas distal to the injury site (McGraw et al., 2001; Xie et al., 2011). However, the astroglial response is a double-edged sword for neuronal cells. Of course, there are considerable benefits obtained from the glial scar formation. It prevents the injury site from spreading to the surrounding normal tissue, so holding back the damage, and filling the lesion cavity (Faulkner et al., 2004). The glial scar helps reconstruct the damaged area and reorganize blood vessels, then epithelial cells can migrate into the scar tissue. The glial scar, however, has been proven to be the main barrier to neural regeneration (Goldshmit et al., 2004; Fernández-Klett and Priller, 2014). There is mounting evidence that Eph/ephrin signaling is involved in this process and influences glial scar formation during CNS injury or diseases. Cell-contact-mediated bidirectional signaling between EphB2 on meningeal fibroblasts and ephrinB2 on reactive astrocytes triggers cellular cascades. These result in the exclusion of meningeal fibroblasts and the development of the glial scar from the injured site and occur early in the spinal cord injury model (Bundesen et al., 2003). Other research showed that astrogliosis was reduced and regeneration of injured corticospinal axons accelerated.
in ephrin B2– mice, thereby resulting in the recovery of motor function after spinal cord injury (Ren et al., 2013). In lesioned EphA4– spinal cords, the astrocytic gliosis and the glial scar were greatly reduced. EphA4– astrocytes failed to respond to the leukemia inhibitory factor or interferon-gamma and inflammatory cytokines in vitro. Neurons grown on EphA4– astrocytes extended longer neurites than on wild-type astrocytes. The application of EphA4 inhibitors in wild-type mice produced a moderate reduction in astrocytic gliosis, promoted axonal regeneration and improved functional outcome following spinal cord hemisection (Goldsmith et al., 2004; Goldsmith et al., 2011).

Glutamate is not only a pivotal excitatory neurotransmitter but also a potential neurotoxin in the CNS. Excessive glutamate signaling can lead to excitotoxic cell death. Eph/ephrin signaling can help the astrocytes in the injured brain maintain the homeostasis of extracellular glutamate. Astrocytic glutamate transporters and astrocytic glutamate uptake capacity decreased, if the clustered EphA4 was applied (Yang et al., 2014). The EphA4-mediated ephrinA3 reverse-signaling controls the glial glutamate transporters and prevents glutamate excitotoxicity developing under pathological conditions (Yang et al., 2014).

**Eph/ephrin signaling mediates neurogenesis and angiogenesis**

In the mature CNS, endogenous neural precursor cells are present in the rostral subventricular zone of the lateral ventricles and the subgranular zone of the dentate gyrus. Under pathophysiological conditions, proliferation of neural precursor cells in the subventricular zone and subgranular zone is triggered. These neuroblasts may migrate toward the lesioned area, and some of them differentiate into new neurons to replace damaged neurons. Eph/ephrin bidirectional signaling contributes to their response to CNS injury by influencing both the differentiation and proliferation of neural precursor cells. EphB3/ephrinB3 regulates the proliferation and differentiation of cells in the subventricular zone and in the rostral migratory stream by controlling levels of p53 (Ricard et al., 2006; Theus et al., 2010; del Valle et al., 2011; Baumann et al., 2013). Blockade of EphB2 plays a role in the neurogenesis and the recovery of neurological function after cerebral cortical infarction in hypertensive rats (Xing et al., 2008). In addition to neurogenesis, neurons control their plasticity by adapting their structure and function to the microenvironmental changes. A series of experiments have shown that Eph/ephrin signaling exhibits an inhibitory effect on neurite outgrowth in damaged CNS. For example, ephrinA5 reverse signaling could induce growth cone collapse and then inhibit axonal regeneration through activating RhoA (Yue et al., 2008). At the same time, ephrinA5-mediated EphA4 forward signaling triggers axonal growth cone collapse via the downstream RacGAP alpha2-chimaerin-dependent signaling pathway (Wegmeyer et al., 2007). Eph/ephrin bidirectional signaling can regulate the oligodendrocyte precursor cells and oligodendrocytes. Eph-ephrin interactions between axons and oligodendrocyte precursor cells control the distribution and migration of oligodendrocyte precursor cells in the optic axonal tracts (Prestoz et al., 2004). It is worth noting that ephrin-B3 expressed in post-natal myelinating oligodendrocytes acts as a myelin-based inhibitor through the combined p75NTR neurotrophin receptor (Benson et al., 2005). It is now relatively well accepted that neurogenesis and angiogenesis are coupled processes.

Eph receptors and their ephrin ligands are also involved in angiogenesis, which is critical for vascular remodeling following CNS injury (Pasquaie, 2008). EphA2 can regulate post-natal angiogenesis. EphA2-deficient endothelial cells were unable to undergo vascular migration and assembly (Brantley-Sieders et al., 2004). UniPR129, a competitive small molecule Eph-ephrin antagonist, blocks angiogenesis at a low concentration *in vitro* (Hassan-Mohamed et al., 2014). The ephrinA5/EphA4 interaction is associated with the epilepsy, and can suppress microvessel remodeling and neogenesis of neurons in a mouse model of temporal lobe epilepsy (Shu et al., 2016).

**Eph/ephrin signaling and neuroinflammation**

Post-injury inflammation is implicated in almost all kinds of CNS injury. Infection, neurodegeneration, trauma even though ischemia stimulate an inflammatory response, which causes the activation of microglia in the brain. Inflammation is beneficial in the clearance of debris caused by necrotic cells. Nevertheless, severe inflammation causes cerebral swelling and vascular dysfunction, aggravating the neuronal damage. There is proof for the involvement of Eph/ephrin proteins in the inflammatory process after CNS injury (Pasquaie, 2008). Inhibition of EphBs receptors by injection of EphB1-Fc (blocker of EphB1 receptor) reduced chronic constrictive injury-induced neuropathic pain and formalin-induced inflammation (Yu et al., 2012). Presynaptic ephrinB2 has also been found to regulate inflammatory pain by regulating the tyrosine phosphorylation of the NMDA receptor (Zhao et al., 2010).

**Conclusions**

Eph/ephrin bidirectional signaling plays a critical role in CNS injury. Signaling through Eph/ephrin complexes mediates neurogenesis and angiogenesis, promotes glial scar formation, regulates homeostasis, inhibits myelination and exaggerates inflammation linked to injury-induced neuropathic pain. However, interaction between Ephs and ephrins ligands is essential for angiogenesis. More specific roles of Eph/ephrin in the injured nervous system are only beginning to be appreciated, such as the paradoxes of EphB1 receptor in the malignant brain (Wei et al., 2017) and the role of EphA10 in the CNS injury or related diseases. Therefore, further studies will generate more comprehensive data. We will continue to explore more roles of Eph/ephrin in the repair of the injured CNS.

**Author contributions:** YW and JSY wrote most of the chapters and drew the figure and the table. LCX, XJH, WW and MJX supervised and proofread the entire review. All authors approved the final version of the paper.

**Conflicts of interest:** The authors declare no competing financial interests.
Financial support: The investigation was supported by the National Natural Science Foundation of China, No. 8137312, 8130021, and the National Basic Research Development Program (973 Program) of China, No. 2011CB504403. The funding bodies played no role in the study design, in the collection, analysis and interpretation of data, in the writing of the report, or in the decision to submit the article for publication.

Copyright license agreement: The Copyright License Agreement has been signed by all authors before publication.

Plagiarism check: Checked twice by iThenticate.

Peer review: Externally peer reviewed.

Open access statement: This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-Non-Commercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

Open peer review report:

Reviewer: Sanusi Mohammad Bello, King Faisal University, Saudi Arabia.

Comments to authors: The article brought forward the emerging ever expanding roles of Eph/Ephrin bidirectional signaling abilities in the injury and repair of the central nervous system. This area of Ephrin signaling has the potential for exploration for more specific roles in the repair of injured nervous system with huge potential for clinical application in the near future. I therefore encourage the author to continue to explore other useful potential applications of the Ephrin signaling. It is a good game to explore the wonders of this important member in the repair of nervous system.

References

Aoto J, Chen L (2007) Bidirectional ephrin/Eph signaling in synaptic functions. Brain Res 1184:72-80.

Battaglia AA, Sekayek A, Grast J, McMahan SB, Gavazzi I (2003) EphB receptors and ephrin-B ligands regulate spinal sensory connectivity and modulate pain processing. Nat Neurosci 6:339-340.

Baumann G, Travieso L, Liebl DJ, Theus MH (2013) Pronounced hypertrophy in the subventricular zone following traumatic brain injury and the neural stem/progenitor cell response. Exp Biol Med (Maywood) 238:830-841.

Becker E, Huynh-Do U, Holland S, Pardon T, Daniel TO, Skolnik EY (2000) Nck-interacting Ste20 kinase couples Eph receptors to Jun N-terminal kinase and integrin activation. Mol Cell Biol 20:1537-1545.

Benson MD, Romero MI, Lush ME, Lu QR, Henikemeyer M, Parada LF (2005) Ephrin-B3 is a myelin-based inhibitor of neurite outgrowth. Proc Natl Acad Sci U S A 102:10694-10699.

Bhakoo KH, Kulkarni A, Baillat L, Baillat V, Oweida A, Gregio A, Calame D, Storjorm A, Horsman N, Albanese C, Venkataraman S, Vihakbar R, Karam SD (2017) Combined EphB2 receptor knockdown with radiation decreases cell viability and invasion in medulloblastoma. Cancer Cell Int 17:41.

Biervert C, Horvath E, Fahrig T (2004) Eph signaling proteins mediate the Nkx2.5-NTF1-dependent mechanism. Nat Neurosci 10:67-76.

Brundin LQ, Scheel TA, Bregman BS, Kroemer LF (2003) Ephrin-B2 and EphB2 regulation of astrocyte-meningeal fibroblast interactions in response to spinal cord lesions in adult rats. J Neurosci 23:7789-7800.

Bunge RP, Puckett WR, Hiester ED (1997) Observations on the pathology of several types of human spinal cord injury, with emphasis on the astrocyte response to penetrating injuries. Adv Neurol 72:305-315.

Carmona MA, Murai KK, Wang L, Roberts AJ, Pasquale EB (2009) Glial ephrin-A3 regulates hippocampal dendritic spine morphology and glutamate transport. Proc Natl Acad Sci U S A 106:12524-12529.

Carter N, Nakamoto T, Hirai H, Hunter T (2002) Ephrin-A1-induced cytoskeletal re-organization requires FAK and p130(cas). Nat Cell Biol 4:565-573.

Choi DH, Ahn JH, Choi IA, Kim JH, Kim BR, Lee J (2016) Effect of task-specific training on Eph/ephrin expression after stroke. BMB reports 49:635-640.

Chunmey ML, Catchpole T, Silvany RE, Kernie SG, Hennekemper M (2007) EphB receptors regulate stem/progenitor cell proliferation, migration, and polarity during hippocampal neurogenesis. J Neurosci 27:13481-13490.

Cowan CA, Hennekemper M (2001) The SH2/SH3 adaptor Grb4 transduces Eph/ephrin reverse signals. Nature 413:174-179.

Cramer KS, Miko JI (2016) Eph/ephrin signaling in nervous system development. F1000Res 5:413.

Dawy A, Robbins SM (2000) Ephrin-A5 modulates cell adhesion and morphology in an integrin-dependent manner. EMBO J 19:5396-5405.

Dawy A, Gale NW, Murray EW, Klinkhofer RA, Soriano P, Feuerstein C, Robbins SM (1999) Compartmentalized signaling by GPI-anchored ephrin-A5 requires the Fyn tyrosine kinase to regulate cellular adhesion. Genes Dev 13:3125-3135.

Dawson MR, Levine JM, Reynolds R (2000) NG2-expressing cells in the central nervous system: are they oligodendroglial progenitors? J Neurosci Res 61:471-479.

Day BW, Stringer BW, Boyd AW (2014) Eph receptors as therapeutic targets in glioblastoma. Br J Cancer 111:1255-1261.

del Valle K, Theus MH, Beetha JR, Liebl DJ, Ricard J (2011) Neural progenitors proliferation is inhibited by EphB3 in the developing subventricular zone. Int J Dev Neurosci 29:9-14.

Dergham P, Ellezam B, Essaqian C, Avedissian H, Lubell WD, McKerracher L (2002) Rho signaling pathway targeted to promote spinal cord repair. J Neurosci 22:6570-6577.

Dickson BJ (2001) Rho GTPases in growth cone guidance. Curr Opin Neurobiol 11:103-110.

Dohrn PK, P. Hunter K, Jones-Bolin S, Chang H, Robinson C, Pritchard S, Zhao H, Ruggeri B (2004) Antiangiogenic and antitumor efficacy of EphA2 receptor antagonist. Cancer Res 64:910-919.

Eichmann A, Makinen T, Altalio K (2005) Neural guidance molecules regulate vascular remodeling and vessel navigation. Genes Dev 19:1013-1021.

Fan R, Enkhjalgal B, Camara R, Yan F, Gong L, Shengtao Yao, Tang J, Chen Y, Zhang JH (2017) Critical role of EphA4 in early brain injury after subarachnoid hemorrhage in rat. Exp Neurol 296:41-48.

Fang Y, Cho KS, Tchedre K, Lee SW, Guo C, Kinouchi H, Fried S, Sun X, Chen DF (2013) Ephrin-A3 suppresses Wnt signaling to control retinal stem cell potency. Stem Cells 31:349-359.

Faulkner JR, Herrmann J, Ee JW, Majesky MW, Sofroniew MV (2004) Reactive astrocytes protect tissue and preserve function after spinal cord injury. J Neurosci 24:2143-2155.

Fernández-Klett F, Priller J (2014) The fibrotic scar in neurological disorders. Brain Pathol 24:404-413.

Flanagan JG, Vanderhaeghen P (1998) The ephrins and Eph receptors in neural development. Annu Rev Neurosci 21:309-345.

Fournier AE, Takizawa BT, Strittmatter SM (2003) Rho kinase inhibition enhances axonal regeneration in the injured CNS. J Neurosci 23:1416-1423.

Fu WY, Chen Y, Sahin M, Zhao XS, Shi L, Bikoff JB, Lai KO, Yung WH, Fu AK, Greenberg ME, Ip NY (2007) Cdk5 regulates EphA4-mediated dendritic spine retraction through an ephrin-A1-dependent mechanism. Nat Neurosci 10:67-76.
Giniger E (2002) How do Rho family GTPases direct axon growth and guidance? A proposal relating signaling pathways to growth cone mechanics. Differentiation 70:385-396.

Goldsmith Y, McLenachan S, Turnley A (2006) Roles of Eph receptors and ephrins in the normal and damaged adult CNS. Brain Res Rev 52:327-345.

Goldsmith Y, Galea MP, Wise G, Bartlett PF, Turnley AM (2004) Axonal regeneration and lack of astrocytic gliosis in EphA4-deficient mice. J Neurosci 24:10064-10073.

Goldsmith Y, Spanevello MD, Tajouri S, Li L, Rogers F, Pearse M, Galea M, Bartlett PF, Boyd AW, Turnley AM (2011) EphA4 blockers promote axonal regeneration and functional recovery following spinal cord injury in mice. PLoS One 6:e24636.

Grunwald IC, Korte M, Woller D, Wilkinson GA, Unsicker K, Lipp HP, Bonhoeffer T, Klein R (2001) Kinase-independent requirement of EphB2 receptors in hippocampal synaptic plasticity. Neuron 32:1027-1040.

Grunwald IC, Korte M, Adelmann G, Plueck A, Kullander K, Adams RH, Frotscher M, Bonhoeffer T, Klein R (2004) Hippocampal plasticity requires postynaptic ephrinB3. Nat Neurosci 7:33-40.

Hafner C, Schmitz G, Meyer S, Bataille F, Hau P, Langmann T, Dietmaier W, Landthaler M, Vogt T (2004) Differential gene expression of Eph receptors and ephrins in benign human tissues and cancers. Clin Chem 50:490-499.

Hamaoka Y, Negishi M, Katoh H (2016) EphA2 is a key effector of the MEK/ERK/RSK pathway regulating glioblastoma cell proliferation. Cell Signal 28:937-945.

Hassan-Mohamed I, Giorgio C, Incerti M, Russo S, Pala D, Pasquale EB, Zanotti I, Vicini P, Barocelli E, Rivara S, Mor M, Lodola A, Tognolini M (2014) UniPR129 is a competitive small molecule Eph-ephrin antagonist blocking in vitro angiogenesis at low micromolar concentrations. Br J Pharmacol 171:5195-5208.

Henderson JT, Georgiou J, Jia Z, Robertson J, Elowe S, Roder JC, Pawson T (2001) The receptor tyrosine kinase EphB2 regulates NMDA-dependent synaptic function. Neuron 32:1041-1056.

Henkemeyer M, Itkis OS, Ngo M, Hickmott PW, Ethell IM (2003) Multiple EphB receptor tyrosine kinases shape dendritic spines in the hippocampus. J Cell Biol 163:1313-1326.

Henkemeyer M, Marengere LE, McGlade J, Olivier JP, Conlon RA, Holmyard DP, Letwin K, Pawson T (1994) Immunolocalization of the Nuk receptor tyrosine kinase suggests roles in segmental patterning of the brain and axonogenesis. Oncogene 9:1001-1014.

Hirai H, Maru Y, Hagiwara K, Nishida J, Takaku F (1987) A novel putative tyrosine kinase encoded by the eph gene. Science 238:1717-1720.

Holland SJ, Gale NW, Mbamalu G, Yancopoulos GD, Henkemeyer M, Putnam W, Bonhoeffer T, Klein R (2001) Bidirectional signalling through the Eph-family receptor Nuk and its transmembrane ligands. Nature 383:722-725.

Holland SJ, Gale NW, Gish GD, Roth RA, Songyang Z, Cantley LC, Henkemeyer M, Yancopoulos GD, Pawson T (1997) Juxtamembrane tyrosine residues couple the Eph family receptor EphB2/Nuk to specific SH2 domain proteins in neuronal cells. EMBO J 16:3877-3888.

Hsueh YP, Sheng M (1998) Eph receptors, ephrins, and PDZs gather in hippocampal synaptic plasticity. Neuron 21:1227-1229.

Huo J (2004) Ephrin signaling in axon guidance. Prog Neuropsycho-endocrinopharmacol Biol Psychiatry 28:813-818.

Jing X, Miwa H, Sawada T, Nakashii I, Kondo T, Miyajima M, Saka-guchi K (2012) Ephrin-A1-mediated dopaminergic neurogenesis and angiogenesis in a rat model of Parkinson’s disease. PLoS One 7:e32019.

Kalo MS, Pasquale EB (1999) Signal transfer by eph receptors. Cell Tissue Res 298:1-9.

Kalo MS, Yu HH, Pasquale EB (2001) In vivo tyrosine phosphorylation sites of activated ephrin-B1 and ephB2 from neural tissue. J Biol Chem 276:38992-38998.

Kania A, Klein R (2016) Mechanisms of ephrin-Eph signalling in development, physiology and disease. Nat Rev Mol Cell Biol 17:240-256.

Khodosevich K, Watanabe Y, Monyer H (2011) EphA4 preserves postnatal and adult neural stem cells in an undifferentiated state in vivo. J Cell Sci 124:1268-1279.

Klein R (2004) Eph/ephrin signaling in morphogenesis, neural development and plasticity. Curr Opin Cell Biol 16:580-589.

Klein R (2009) Bidirectional modulation of synaptic functions by Eph/ ephrin signaling. Nat Neurosci 12:15-20.

Krusche B, Ottone C, Clements MP, Johnstone ER, Goetsch K, Lieven H, Mota SG, Singh P, Khadayate S, Ashraf A, Davies T, Pollard SM, De Paola V, Roncaroli F, Martinez-Torrecaudadra J, Bertone P, Parreira S (2016) EphrinB2 drives perivasculare invasion and proliferation of glioblastoma stem-like cells. Elife 5:e14845.

Kullander K, Klein R (2002) Mechanisms and functions of Eph and ephrin signaling, Nat Rev Mol Cell Biol 3:475-486.

Lackmann M, Oates AC, Dottori M, Smith FM, Do C, Power M, Kравets L, Boyd AW (1998) Distinct subdomains of the EphA3 receptor mediate ligand binding and receptor dimerization. J Biol Chem 273:20228-20237.

Lai KO, Chen Y, Po HM, Lok KC, Gong K, Ip NY (2004) Identification of the Jak/Stat proteins as novel downstream targets of EphA4 signaling in muscle: implications in the regulation of acetylcholine-esterase expression. J Biol Chem 279:13383-13392.

Lawrenson JD, Wimmer-Kleikamp SH, Lock P, Schoenwaelder SM, Down M, Boyd AW, Alewod RF, Lackmann M (2002) Ephrin-A5 induces rounding, blebbing and de-adhesion of Eph-A3-expressing 293T and melanoma cells by CrkII and Rho-mediated signalling. J Cell Sci 115:1059-1072.

Lehmann M, Fournier A, Selles-Narvavo I, Dergham P, Sebek A, Leclerc N, Tiggy G, McKerracher L (1999) Inactivation of Rho signalling pathway promotes CNS axon regeneration. J Neurosci 19:7537-7547.

Liel DJ, Morris CJ, Henkemeyer M, Parada LF (2003) mRNA expression of ephrins and Eph receptor tyrosine kinases in the neonatal and adult mouse central nervous system. J Neurosci 71:2-72.

Lim BK, Matsuda N, Poo MM (2008) Ephrin-B reverse signaling promotes structural and functional synaptic maturation in vivo. Nat Neurosci 11:160-169.

Lisabeth EM, Falivell G, Pasquale EB (2013) Eph receptor signaling and ephrins. Cold Spring Harb Perspect Biol 5:a009159.

Lu Q, Sun EE, Klein RS, Flanagan JG (2001) Ephrin-B reverse signaling is mediated by a novel PDZ-RGS protein and selectively inhibits G protein-coupled chemotraction. Cell 105:69-79.

Macrae M, Neve RM, Rodríguez-Viciana P, Haqq C, Yeh C, Chen J, Gray JW, McCormick F (2005) A conditional feedback loop regulates Ras activity through EphA2. Cancer Cell 8:111-118.

Martone ME, Holash JA, Bayardo A, Pasquale EB, Ellisman MH (1997) Immunolocalization of the receptor tyrosine kinase EphA4 in the adult rat central nervous system. Brain Res 771:238-250.

McKraw J, Hiebert GW, Steves JD (2001) Modulating astrogliosis after neurotrauma. J Neurosci Res 65:169-180.

Mellitzer G, Xu Q, Wilkinson DG (1999) Eph receptors and ephrins restrict cell intermingling and communication. Nature 400:77-81.

Miranda JD, White LA, Marcillo AE, Willson CA, Jagid J, Whittemore AR, Kallione K (1999) Induction of Eph B3 after spinal cord injury. Exp Neurol 156:218-222.

Murai KK, Pasquale EB (2002) Can Eph receptors stimulate the mind? Neuro 33:159-162.

Murai KK, Nguyen LN, Irie F, Yamaguchi Y, Pasquale EB (2003) Control of hippocampal dendritic spine morphology through ephrin-A3/EphA4 signaling. Nat Neurosci 6:153-160.

Nimmul AS, Yatsula BA, Bar-Sagi D (1998) Coupling of Ras and Rac guanosine triphosphatases through the Ras exchanger Sos. Science 279:560-563.

O’Leary DD, Wilkinson DG (1999) Eph receptors and ephrins in the normal and damaged adult CNS. Brain Res Rev 293:172-179.

Olivieri G, Miescher GC (1999) Immunohistochemical localization of EphA5 in the adult human central nervous system. J Histochem Cytochem 47:855-861.

Palmer A, Zimmer M, Ermann KS, Eulenburg V, Porthin A, Heu mann R, Deutsch U, Klein R (2002) EphrinB phosphorylation and reverse signaling: regulation by Src kinases and PTP-βL phosphatase. Mol Cell 9:725-737.

Pasquale EB (2005) Eph receptor signalling casts a wide net on cell behaviour. Nat Rev Mol Cell Biol 6:462-475.
Pasquale EB (2008) Eph-ephrin bidirectional signaling in physiology and disease. Cell 133:38-52.

Pasquale EB (2016) Exosomes expand the sphere of influence of Eph receptors and ephrins. J Cell Biol 214:5-7.

Prestoz L, Chatzopoulos E, Lemkine G, Spasny S, Lebrass B, Kagawa T, Ikenaka K, Zalc B, Thomas JL (2004) Control of axonophilic migration of oligodendrocyte precursor cells by Eph-ephrin interaction. Neuron Glia Biol 1:73-83.

Ren Z, Chen X, Yang J, Kress BT, Tong J, Liu H, Takano T, Zhao Y, Nedergaard M (2013) Improved axonal regeneration after spinal cord injury in mice with conditional deletion of ephrin B2 under the GFAP promoter. Neuroscience 241:89-99.

Ricard J, Salinas J, Garcia L, Liebl DJ (2006) EphrinB3 regulates cell proliferation and survival in adult neurogenesis. Mol Cell Neurosci 31:713-722.

Rodenas-Ruano A, Perez-Pinzon MA, Green EJ, Henkemeier M, Liebl DJ (2006) Distinct roles for ephrinB3 in the formation and function of hippocampal synapses. Dev Biol 292:34-45.

Ruan JP, Zhang HX, Lu XF, Liu YP, Cao JL (2010) EphrinB3/EphB signaling is involved in modulation of spinal nociceptive processing through a mitogen-activated protein kinase-dependent mechanism. Anesthesiology 112:1234-1249.

Sahin M, Greer PL, Lin MZ, Poucher H, Eberhart J, Schmidt S, Wright TM, Shamah SM, O’Connell S, Cowan CW, Hu L, Goldberg JL, Debant A, Corfas G, Krull CE, Greenberg ME (2005) Eph-dependent tyrosine phosphorylation of ephexin1 modulates growth cone collapse. Neuron 46:191-204.

Salcedo R, Wasserman K, Young HA, Grimm MC, Howard OM, Anver MR, Kleinman HK, Murphy WP, Oppenheim JJ (1999) Vascular endothelial growth factor and basic fibroblast growth factor induce neovascularization induced by stromal-derived factor-1alpha. Am J Pathol 154:1125-1135.

Schnell L, Fearn S, Klassen H, Schwab ME, Perry VH (1999) Acute inflammatory responses to mechanical lesions in the CNS: differences between brain and spinal cord. Eur J Neurosci 11:3648-3658.

Shamah SM, Lin MZ, Goldberg JL, Estrich S, Sahin M, Hu L, Bazalkova M, Neve RL, Corfas G, Debant A, Greenberg ME (2001) EphA receptors regulate growth cone dynamics through the novel guanine nucleotide exchange factor ephexin. Cell 105:233-244.

Shu Y, Xiao B, Wu Q, Liu T, Du Y, Tang H, Chen S, Feng L, Long L, Li Y (2016) The EphA5-EphA4 interaction modulates neurogenesis and angiogenesis by the p-Akt and p-ERK pathways in a mouse model of TLE. Mol Neurobiol 53:561-576.

Slack S, Battaglia A, Cibert-Goton V, Gavazzi I (2010) EphrinB2 induces tyrosine phosphorylation of NR2B via Src-family kinases during inflammatory hyperalgesia. Neuroscience 156:175-185.

Sobel RA (2005) Ephrin A receptors and ligands in lesions and normal-appearing white matter in multiple sclerosis. Brain Pathol 15:35-45.

Song XJ, Cao JL, Li HC, Zheng JH, Song XS, Xiong LZ (2008) Upregulation and redistribution of ephrinB and EphB receptor in dorsal root ganglion and spinal dorsal horn neurons after peripheral nerve injury and dorsal rhizotomy. Eur J Pain 12:1031-1039.

Steinle JJ, Meiningjer CJ, Forough R, Wu G, Wu MH, Granger HJ (2002) Eph B4 receptor signaling mediates endothelial cell migration and proliferation via the phosphatidylinositol 3-kinase pathway. J Biol Chem 277:43830-43835.

Suetherlin P, Marler KM, Dresher U (2012) Axonal ephrinA/EphA interactions, and the emergence of order in topographic projections. Semin Cell Dev Biol 23:1-6.

Takasu MA, Dalva MB, Zigmond RE, Greenberg ME (2002) Modulation of NMDA receptor-dependent calcium influx and gene expression through EphB receptors. Science 295:491-495.

Taylor H, Campbell J, Nokes CD (2017) Ephs and ephrins. Curr Biol 27:890-895.

Theus MH, Ricard J, Bethea JR, Liebl DJ (2010) EphB3 limits the expansion of neural progenitor cells in the subventricular zone by regulating p53 during homeostasis and following traumatic brain injury. Stem Cells 28:1231-1242.

Tong J, Eloew S, Nash P, Pawsan T (2003) Manipulation of EphB2 regulatory motifs and SH2 binding sites switches MAPK signaling and biological activity. J Biol Chem 278:6111-6119.

Torres R, Firestein BL, Dong H, Staudinger J, Olson EN, Huganir RL, Breit DS, Gale NW, Yanacopoulos GD (1998) PDZ proteins bind, cluster, and synthetically colocalize with Eph receptors and their ephrin ligands. Neuron 21:1453-1463.

Wegmeyer H, Egea J, Rabe N, Gezelius H, Filosa A, Enjin A, Vartoqueux F, Deininger K, Schnutgen F, Brose N, Klein R, Kullander K, Betz A (2007) EphA4-dependent axon guidance is mediated by the RacGAP alpha2-chimaerin. Neuroph 55:756-767.

Wei W, Wang H, Ji S (2017) Paradoxes of the EphB1 receptor in malignant brain tumors. Cancer Cell Int 17:21.

Wilkinson DG (2001) Multiple roles of Eph receptors and ephrins in neural development. Nat Rev Neurosci 2:155-164.

Willson CA, Irazarry-Ramirez M, Gaskins HE, Cruz-Orenlo L, Figueroa JD, Whittemore SR, Miranda JD (2002) Upregulation of EphA receptor expression in the injured adult rat spinal cord. Cell Transplant 11:229-239.

Wu G, Lv G, Zhi XD (2012) Expression of EphB3 receptor protein in injured spinal cord tissues of rats. Zhongguo Zuzhi Gongcheng Yanjiu 16:8671-8674.

Xie M, Yi C, Luo X, Xu S, Yu Z, Tang Y, Zhu W, Du Y, Jia L, Zhang Q, Dong Q, Zhu W, Zhang X, Bu B, Wang W (2011) Glial gap junctional communication involvement in hippocampal damage after middle cerebral artery occlusion. Ann Neurol 70:121-132.

Xing S, He Y, Ling L, Hou Q, Yu J, Zeng J, Pei Z (2008) Blockade of EphB2 enhances neurogenesis in the subventricular zone and improves neurological function after cerebral cortical infarction in hypertensive rats. Brain Res 1230:237-246.

Yang J, Luo X, Huang X, Ning Q, Xie M, Wang W (2014) Ephrin-A3 reverse signaling regulates hippocampal neuronal damage and astrocytic glutamate transport after transient global ischemia. J Neurochem 131:383-394.

Yu LN, Zhou X, Yu J, Huang H, Jiang LS, Zhang FJ, Cao JL, Yan M (2012) PI3K contributed to modulation of spinal nociceptive information related to ephrinB2/EphBs. PLoS One 7:e40930.

Yue X, Dreyfus C, Kong TA, Zhou R (2008) A subset of signal transduction pathways is required for hippocampal growth cone collapse induced by ephrin-A5. Dev Neurobiol 68:1269-1286.

Zhao J, Yuan G, Cendan CM, Nasser MA, Lagerstrom MC, Kullander K, Gavazzi I, Wood JN (2010) Nociceptor-expressed ephrin-B2 regulates inflammatory and neuropathic pain. Mol Pain 6:77.

Zhou N, Zhao WD, Liu DX, Liang Y, Fang WG, Li B, Chen YH (2011) Blockade of ephrin-A5/EphA4 interaction modulates neurogenic hypertensive rats. Brain Res 131:38-52.